Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11257563 | 0.84 | KMT2A (0.38) | DYRK1AKMT2APOLB | |
| SCHEMBL30450250 | 0.82 | KMT2A (0.36) | DYRK1AKDM4EHPGDGAAKMT2A | |
| SCHEMBL2631879 | 0.78 | KDM4E (0.45) | KDM4EGAAKMT2AALDH1A1TSHR | |
| SCHEMBL7013976 | 0.76 | KDM4E (0.40) | DYRK1AKDM4EHPGDHSD17B10GAA | |
| SCHEMBL949563 | 0.76 | KDM4E (0.48) | DYRK1AKDM4EHPGDHSD17B10GAA | |
| SCHEMBL5254960 | 0.76 | KMT2A (0.34) | DYRK1AKMT2ADAO | |
| SCHEMBL20471245 | 0.74 | ALPL (0.65) | KDM4EHPGDHSD17B10ALDH1A1TP53 | |
| SCHEMBL15648169 | 0.72 | — | — | |
| SCHEMBL17416595 | 0.72 | POLB (0.42) | DYRK1AKDM4EHPGDHSD17B10GAA | |
| SCHEMBL27535230 | 0.72 | NOTUM (0.39) | DYRK1AKDM4EHPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-3713931-B1 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCH (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240351988-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND THEIR USE IN THE TREATMENT OF DISEASES AND DISORDERS | ALLIANTHERA BOSTON INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-4402130-A1 | 2-ARYL OR HETEROARYL-3-OXO-4-CARBAMIDE-6-CYCLIC-DIHYDROPYRAZINE ARYL HYDROCARBON RECEPTOR MODULATORS AND THEIR USE IN THE TREATMENT OF DISEASES AND DISORDERS | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-07-24 | — | — | EP | disclosed |
| CN-118234710-A | 2-Aryl or heteroaryl-3-oxo-4-carboxamide-6-cyclo-dihydropyrazine aryl hydrocarbon receptor modulators and use thereof in the treatment of diseases and conditions | 元启(苏州)生物制药有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1723137-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | Aventis Pharma S.A. (FR) | 2006-11-22 | — | — | EP | disclosed |
| CN-1741999-A | Pyridazinone derivatives as GSK-3 beta inhibitors | AVENTIS PHARMA GMBH (DE) | 2006-03-01 | — | — | CN | disclosed |
| EP-1581505-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085231-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2005-09-15 | — | — | WO | disclosed |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | DYRK1A 2563/4885KDM4E 1046/4885HPGD 1439/4885 |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | DYRK1A 2372/4885KDM4E 3201/4885HPGD 2361/4885 |
| US-20050026918-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | C5, ADRA2C, ADRA1A | DYRK1A 2063/4885KDM4E 3541/4885HPGD 1951/4885 |
| US-20240351988-A1 | ARYL HYDROCARBON RECEPTOR MODULATORS AND THEIR USE IN THE TREATMENT OF DISEASES AND DISORDERS | AHR, ARNT, HAVCR2 | DYRK1A 4052/4885KDM4E 3039/4885HPGD 743/4885 |
| US-12428427-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | DYRK1A 3697/4885KDM4E 2935/4885HPGD 1686/4885 |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | DYRK1A 1513/4885KDM4E 818/4885HPGD 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.